Search results for: Mycoplasma pneumoniae IgG ELISA kit
Error loading info... Pleas try again later.
#20701743 2010/08/11 To Up
Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.
Mycoplasma pneumoniae is responsible for acute respiratory tract infections (RTIs) common in children and young adults. As M. pneumoniae is innately resistant to beta-lactams antibiotics usually given as the first-line treatment for RTIs, specific and early diagnosis is important in order to select the right treatment. Serology is the most used diagnostic method for M. pneumoniae infections.Hélène Nuyttens, Camille Cyncynatus, Hélène Renaudin, Sabine Pereyre, Cécile Bébéar
2744 related Products with: Identification, expression and serological evaluation of the recombinant ATP synthase beta subunit of Mycoplasma pneumoniae.
100 ul100 ul100ul100ul10 μg251 mg51mg 5 G50Related Pathways
#12806926 // To Up
[Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].
We evaluated the utility of a rapid detection kit for Mycoplasma pneumoniae (Mp)-specific IgM antibody, ImmunoCard (IC) Mycoplasma Test (Meridian Bioscience, USA), with regard to mycoplasmal infection during childhood. For this purpose, 30 serum samples were obtained from 23 pediatric patients with serologically proved mycoplasmal pneumonia at and younger than 16 years of age. The diagnosis of mycoplasmal infection was made by means of a particle agglutination (PA) method, which was on the basis of 1) a four fold or greater rise with paired sera or 2) at and more than 1:640 with a single, acute phase serum. In addition to the IC test, Mp-specific IgM and IgG antibodies were measured by ELISA tests (Zeus, USA) for comparison. A final observation time for colorization in the IC test was prolonged to 10 min in this study. The reason for this was because only 8 samples which were obtained 5 days or more after the onset of fever (37.5 degrees C) were judged to be positive when the observation time was confined to 5 min as the manufacturer recommended. A judgment was always made by more than one persons. Since we intended to find out the diagnostic capability of the IC test using an acute phase single serum, we focused on 18 cases for which samples were obtained within 5 days of the onset of fever. As a result, 13 (72%) cases were judged to be positive for Mp by the IgM ELISA test, 6 (33%) cases, including 5 cases in which the result was interpreted to be positive by a 10-min observation, were judged to be positive by the IC test, and 4 (22%) cases were judged to be positive by the PA test when titers of at and more than 1:320 by an acute phase single serum were interpreted as significant. Through this study we felt that the sensitivity of the IC test was not so high as have been previously reported in the literatures (the IC test was occasionally positive even in the range of < 1:40 by a PA test). On the other hand, we believe that the 10-min observation for final colorization did not significantly affect the specificity of the IC test as long as it was compared with the results by the ELISA IgM test. So far, the rapidity in obtaining results, and the simplicity of handling by which the test can be performed in an outpatient clinic, are thought to be the major advantages of the IC test.Mitsuo Narita, Takehiro Togashi
2847 related Products with: [Evaluation of a rapid IgM antibody detection kit for diagnosis of Mycoplasma pneumoniae infection during childhood].
120tests100ug200 ug96 tests 100ul16-22 Sample Kit100ug0.2 mg 100ul12tests0.1 ml25 µgRelated Pathways
#12376023 // To Up
Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.
A prospective study was conducted to identify and characterize hospitalizations for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with serologic evidence of infection with Mycoplasma pneumoniae (Mp). Two hundred forty hospitalizations for AECOPD were included in a 17-month prospective study. Paired sera were obtained for each of the hospitalizations and were tested serologically for Mp using a commercial enzyme immunoassay (EIA) kit. Only significant changes, according to the formula in the manufacturer's instructions, in antibody titers for IgM and/or IgG and/or IgA were considered diagnostic for Mp infection. In 34 hospitalizations (14.2%) the serologic tests for Mp were positive (MpH). In 29 of these hospitalizations (85%) a significant change in IgA was found. In 11 of these hospitalizations (32%) the only change identified was in IgA. In 24 MpH (71%) there was serologic evidence for infection with at least one other respiratory pathogen. In comparison to the 206 hospitalizations without serologic evidence of infection with Mp, MpH had higher rates of inhaled steroid therapy (41% vs. 24%, p = 0.033) and a longer time interval between the appearance of dyspnea and hospitalization (6.6 +/- 3.8 days vs. 5.0 +/- 3.5 days, p = 0.012). There were no significant differences between these two groups in a broad spectrum of patient- and exacerbation-related clinical variables. Specific antibiotic therapy for Mp in the MpH group did not shorten the hospital stay. Serologic evidence of Mp infection is common in patients hospitalized for AECOPD, and is usually based on changes in specific IgA antibody titers. In most MpH another respiratory pathogen can be identified. The vast majority of clinical characteristics are the same in patients with and without serologic evidence of infection with Mp. The practical implications of these findings should be clarified in further studies.David Lieberman, Devora Lieberman, M Ben-Yaakov, O Shmarkov, Y Gelfer, R Varshavsky, B Ohana, Z Lazarovich, I Boldur
2173 related Products with: Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD.
96 Tests96 tests96 Tests 5 G1mg196 Tests96 testsRelated Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]